Bristol Myers director adds 607 deferred units
Bristol Myers Squibb director Phyllis R. Yale reported a routine compensation-related grant of deferred share units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bristol Myers Squibb director Phyllis R. Yale reported a routine compensation-related grant of deferred share units. On this Form 4, she acquired 607.428 Deferred Share Units, each economically valued at $57.62, tied to the company’s common stock. These units are part of a non-employee director compensation program and will be converted into common shares when she leaves the board or at a future date she previously selected.
Following this grant, Yale holds a total of 44,986.288 deferred share units, which also reflect deferred compensation and reinvested dividends under the 1987 Deferred Compensation Plan for Non-Employee Directors. This filing reflects a non-market, derivative award rather than an open-market stock purchase or sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Share Units | 607.428 | $57.62 | $35K |
Footnotes (2)
- F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
AI-generated analysis. How Rhea-AI works. Not financial advice.